Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010121923) RSPONDIN-3 INHIBITION IN BONE DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/121923 International Application No.: PCT/EP2010/054817
Publication Date: 28.10.2010 International Filing Date: 13.04.2010
IPC:
A61K 39/395 (2006.01) ,C07K 16/18 (2006.01) ,A61P 19/08 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19
Drugs for skeletal disorders
08
for bone diseases, e.g. rachitism, Paget's disease
Applicants:
RAWADI, Georges [FR/FR]; FR (UsOnly)
NIEHRS, Christof [DE/DE]; DE (UsOnly)
DEUTSCHES KREBSFORSCHUNGSZENTRUM [DE/DE]; Im Neuenheimer Feld 280 69120 Heidelberg, DE (AllExceptUS)
Galapagos SASU [FR/FR]; 102 Avenue Gaston Roussel F-93230, Romainville, FR (AllExceptUS)
Inventors:
RAWADI, Georges; FR
NIEHRS, Christof; DE
Agent:
WEIß, Wolfgang; Weickmann & Weickmann Postfach 860 820 81635 München, DE
Priority Data:
61/169,40615.04.2009US
Title (EN) RSPONDIN-3 INHIBITION IN BONE DISORDERS
(FR) INHIBITION DE LA RSPONDINE-3 DANS DES TROUBLES OSSEUX
Abstract:
(EN) The present invention relates to uses of antagonists of Rspondin-3 (Rspo3) polypeptides or Rspondin-3 nucleic acids. The invention is based on the demonstration that partial deficiency of Rspo3 leads to a significant increase of bone mass. These results indicate a major role for Rspo3 as a bone anabolic marker or target. Thus, the invention also relates to the use of Rspo3 antagonists in the treatment of osteopenia disorders, particularly in conditions associated with increased bone resorption.
(FR) La présente invention porte sur des utilisations d'antagonistes de polypeptides de Rspondine-3 (Rspo3) ou d'acides nucléiques de Rspondine-3. L'invention est basée sur la démonstration qu'un déficit partiel en Rspo3 conduit à une augmentation significative de la masse osseuse. Ces résultats indiquent un rôle majeur de Rspo3 en tant que marqueur ou cible anabolique osseux. Ainsi, l'invention porte également sur l'utilisation d'antagonistes de Rspo3 dans le traitement de troubles d'ostéopénie, en particulier dans des états associés à une résorption osseuse accrue.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)